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A B S T R A C T   
Background: Dravet syndrome is a rare, severe pediatric epileptic encephalopathy associated with intellectual and 
motor disabilities. Proteomic profiling in a mouse model of Dravet syndrome can provide information about the 
molecular consequences of the genetic deficiency and about pathophysiological mechanisms developing during 
the disease course. 
Methods: A knock-in mouse model of Dravet syndrome with Scn1a haploinsufficiency was used for whole pro-
teome, seizure, and behavioral analysis. Hippocampal tissue was dissected from two- (prior to epilepsy mani-
festation) and four- (following epilepsy manifestation) week-old male mice and analyzed using LC-MS/MS with 
label-free quantification. Proteomic data sets were subjected to bioinformatic analysis including pathway 
enrichment analysis. The differential expression of selected proteins was confirmed by immunohistochemical 
staining. 
Results: The findings confirmed an increased susceptibility to hyperthermia-associated seizures, the development 
of spontaneous seizures, and behavioral alterations in the novel Scn1a-A1873V mouse model of Dravet syn-
drome. As expected, proteomic analysis demonstrated more pronounced alterations following epilepsy mani-
festation. In particular, proteins involved in neurotransmitter dynamics, receptor and ion channel function, 
synaptic plasticity, astrogliosis, neoangiogenesis, and nitric oxide signaling showed a pronounced regulation in 
Dravet mice. Pathway enrichment analysis identified several significantly regulated pathways at the later time 
point, with pathways linked to synaptic transmission and glutamatergic signaling dominating the list. 
Conclusion: In conclusion, the whole proteome analysis in a mouse model of Dravet syndrome demonstrated 
complex molecular alterations in the hippocampus. Some of these alterations may have an impact on excitability 
or may serve a compensatory function, which, however, needs to be further confirmed by future investigations. 
The proteomic data indicate that, due to the molecular consequences of the genetic deficiency, the pathophys-
iological mechanisms may become more complex during the course of the disease. As a result, the management 
of Dravet syndrome may need to consider further molecular and cellular alterations. Ensuing functional follow- 
up studies, this data set may provide valuable guidance for the future development of novel therapeutic 
approaches.   
Abbreviation list: MS, Mass spectrometry; LC-MS/MS, Liquid chromatography with tandem mass spectrometry; Hprt, Hypoxanthine-guanine phosphoribosyl-
transferase; VEGF, Vascular endothelial growth factor; JAK-STAT, The Janus kinase/signal transducers and activators of transcription; PSD, Postsynaptic density; 
CaMK, Calcium/calmodulin-dependent protein kinases; nNOS, Neuronal nitric oxide synthase; NO, Nitric oxide; SE, Status epilepticus. 
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1. Introduction 
In the vast majority of patients with Dravet syndrome, an SCN1A 
mutation can be identified, which results in functional deficiency of the 
encoded sodium channel subunit Nav1.1 (Brunklaus and Zuberi, 2014; 
Dravet and Oguni, 2013). Dravet syndrome is characterized by seizures 
with a poor pharmacoresponse to available antiepileptic drugs (Wallace 
et al., 2016). Moreover, there is a high risk of sudden unexpected death 
in epilepsy (SUDEP) in Dravet patients (Kalume, 2013). Thus, despite 
the licensing of orphan drugs for Dravet syndrome, there is an unmet 
clinical need for novel therapeutic approaches tailored to the disease. 
While knowledge about the genetic cause provides a basis for the 
rational development of precision medicine approaches (Dugger et al., 
2018), the elucidation of the molecular consequences of the genetic 
deficiency can further improve our understanding of the pathophysio-
logical mechanisms involved, thus providing a broader framework for 
the identification of novel targets and the subsequent development of 
innovative therapeutic strategies. 
Large-scale proteomic profiling constitutes one of the most prom-
ising tools providing comprehensive information about epilepsy- 
associated alterations at a functionally relevant molecular level. Dur-
ing recent years, initial studies have identified proteome alterations in 
models of acquired epilepsy (Bitsika et al., 2016; Keck et al., 2017; Keck 
et al., 2018; Li et al., 2010; Liu et al., 2008; Walker et al., 2016). 
However, respective data for genetic epilepsies are rather limited; they 
focus on models of genetic absence epilepsy and fragile X syndrome 
(Danış et al., 2011; Liao et al., 2008; Xu et al., 2018). To our knowledge, 
the molecular consequences of Scn1a genetic deficiency are yet to be 
studied by quantitative whole proteome analysis. Characterizing the 
molecular signature of Dravet syndrome may therefore contribute to the 
understanding of disease-associated alterations in neuronal 
homeostasis. 
Here, we completed a large-scale proteomic profiling study in a novel 
conditional mouse line carrying a human Dravet syndrome SCN1A 
mutation (Kuo et al., 2019; Ricobaraza et al., 2019). The analysis 
focused on two time points: prior to and following the onset of sponta-
neous recurrent seizures. This design obtained information about the 
molecular patterns occurring both during epileptogenesis and following 
epilepsy manifestation. 
Taken together, our findings improve the understanding of the 
complex molecular consequences of SCN1A genetic deficiency and 
provide a basis for the discovery of novel innovative targets, both for the 
prevention of disease progression and therapeutic management of Dra-
vet syndrome. 
2. Material and methods 
2.1. Genetic mouse model: breeding and genotyping 
Breeding colonies of the parental lines B6(Cg)-Scn1atm1.1Dsf/J 
(#026133(Kuo et al., 2019; Ricobaraza et al., 2019)) and 129S1/Sv- 
Hprttm1(CAG-cre)Mnn/J (#004302(Tang et al., 2002)) were generated 
based on breeding pairs purchased from the Jackson Laboratory (Bar 
Harbor, Maine, USA). Conditional knock-in male mice with a floxed 
Scn1a (mutation A1783V in exon 26) were crossed with female mice 
heterozygous for Cre recombinase (X-linked to neuronal promoter Hprt 
gene). The offspring (F1 hybrids) were heterozygous Dravet mice car-
rying the A1783V mutation (wildtype or heterozygous for Cre recom-
binase) or wildtype mice without the A1783V mutation (wildtype or 
heterozygous for Cre recombinase). Since the presence of Cre did not 
affect the phenotype, animals were divided into two groups depending 
on the presence of the A1783V-Scn1a mutation: an experimental group 
(in the following referred to as Dravet mice) and a control group 
(wildtype mice). This mouse line was chosen for the experiments 
because A1783V represents one of the clinically relevant mutations 
affecting S6 transmembrane region of domain IV of the alpha subunit of 
type I voltage-gated sodium channels in patients with Dravet syndrome 
(Lossin, 2009). 
The genotype of the animals was confirmed by PCR, using 5′- 
GCAACTCTTCACATGGTACTTTCA-3′, 5′-GCACCTCTCCTCCTTAGA- 
ACA-3′ and 5′-GGAGAAACACGAGCAGGAAG-3′ primers: wildtype, 164 
bp; heterozygous pre Cre, 164, 198 and 410 bp; and heterozygous post 
Cre, 164 and 198 bp (Fig. 1A). The presence of Cre recombinase in mice 
was also confirmed by PCR, using 5′-CTGGTGCTTTACGG-TATCGC-3′, 
5′-TTCATAGAGACAAGGAATGTG-TCC-3′ and 5′-AATCCA-GCAGGT-
CAGCAAAG-3′ primers: WT allele, 217 bp; Cre allele, 450 bp. 
Experiments were approved by the responsible government of Upper 
Bavaria (license number 55.2-1-54-2532-166-2015 and 55.2-1-54-2532- 
168-2016). All experiments were conducted in accordance with the EU 
directive 2010/63/EU for animal experiments and the German Animal 
Welfare act. All experiments were planned and carried out considering 
the ARRIVE guidelines and the Basel declaration (http://www.basel. 
declaration.org) including the 3R concept. 
The brain tissue from twenty mice was used for proteomic analysis 
with five animals per genotype and time point. Sections from four 
wildtype and four Dravet mice aged four weeks were also used for the 
qualitative immunohistochemical analysis of selected proteins. 
An additional group of animals was used for the phenotypic char-
acterization of Dravet mice. From 38 heterozygous mutant mice, 23 (11 
male; 12 female) survived the phase around weaning, which was char-
acterized by a high seizure-associated mortality rate. Data from these 
animals were compared with those from 21 wildtype littermate controls 
(11 male; 10 female). One wildtype and one Dravet female mouse from 
this group were later used for EEG-telemetry recordings. 
In addition, baseline data from 22 heterozygous mutant mice were 
considered for seizure monitoring based on parallel video monitoring 
and telemetric EEG recordings. These animals were also prepared for 
ECG recordings and were further used in a separate study assessing the 
effects of ketogenic diet in Dravet mice (Miljanovic et al., accepted). 
2.2. Housing of animals 
Each litter was housed in individually ventilated cages (Tecniplast, 
Hohenpeißenberg, Germany) from birth until weaning (three weeks). 
Following this phase, mice were housed 3–5 animals per standard 
Makrolon type III cage (Ehret, Emmendingen, Germany). In order to 
confirm the presence of seizures, animals used for brain tissue sampling 
and proteomic analysis were single housed in Makrolon type II open 
cages following weaning (Ehret, Emmendingen, Germany). Animals 
used for behavioral assessments were single housed two weeks prior to 
behavioral assessment. The order of cages in the rack was randomized 
(randomizer.org). 
Each cage was supplied with two nestlets (Ancare, Bellmore, New 
York, USA), one animal house (Tecniplast, Hohenpeißenberg, Germany; 
Zoonlab GmbH, Castrop-Rauxel, Germany) and fresh sawdust as 
bedding material once per week (Lignocel, Rosenberg, Germany). 
Standard conditions in the animal facility were: lights on from 6 am to 6 
pm, temperature 22 ± 2 ◦C, and humidity 50 ± 10%. Animals received 
food (ssniff® R/M-H, Sniff, Soest, Germany) and water ad libitum with 
Dietgel76A offered as a supplement (Sniff, Soest, Germany) between 
postnatal days P14 and P26. 
2.3. Brain samples for proteomic analysis 
Brain samples were obtained at two different time points from five 
mice per genotype and time point. Two-week-old mice (early time point, 
prior to seizure onset) were euthanized by decapitation whilst the four- 
week-old mice (later time point) were euthanized by cervical disloca-
tion. Hippocampal tissue from the left hemisphere was dissected and 
fresh frozen in liquid nitrogen (Besamungsstation München-Grub, 
Poing, Germany) using 1.5 ml Protein LoBind Tubes (Eppendorf, 
Wesseling-Berzdorf, Germany. The experimenter was blinded to animal 
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genotype and the order of animals for dissection was randomized (rando 
mizer.org). Samples were frozen and stored at − 80 ◦C until analysis. The 
right brain hemisphere was collected and left in 4% PFA solution for 24 
h and then switched to 30% sucrose solution, all at 4 ◦C. The brain was 
cut into 40 μm coronal sections, which were later used for 
immunohistochemistry. 
2.4. Proteome analysis 
Untargeted proteome analysis was carried out by an experimenter 
not involved in the in vivo experiments to avoid any expectation- 
triggered bias. Snap frozen hippocampus samples were directly bead 
milled with a Precellys homogenizer (Peqlab, Lutterworth, U.K.) in 
extraction buffer (10 mM Tris-HCl pH 7.6 with 1% NP40, 10 mM NaCl 
and complete protease inhibitors) as previously described (Molin et al., 
2015). The total protein concentration in the sample was measured by 
the Bradford assay. A modified filter-aided sample preparation (FASP) 
method was used for the digestion of 10 μg of total protein per sample as 
described (Lepper et al., 2018). A Q Exactive HF mass spectrometer was 
used for proteomic screening (ThermoFisher Scientific, Dreieich, Ger-
many) with operation in the data independent acquisition (DIA) mode 
(Lepper et al., 2018). Per sample, one injection unit of the HRM Cali-
bration Kit (Biognosys, Schlieren, Switzerland, #Ki-3003) was used for 
spiking 1 μg of peptides for indexing of retention time. Samples were 
loaded automatically onto the UPLC system (Ultimate 3000, Dionex, 
Sunnyvale, CA). The system contained a nano trap column (inner ∅ =
300 μm × 5 mm, packed with Acclaim PepMap100 C18, 5 μm, 100 Å; LC 
Packings, Sunnyvale, CA). Following 5 min of elution from the trap 
column, the peptides were separated by reversed-phase chromatography 
(Acquity UPLC M-Class HSS T3 Column, 1.8 μm, 75 μm × 250 mm; 
Waters, Milford, MA) using a 7–27% gradient of acetonitrile (flow rate of 
250 nl/ min, 90 min) followed by two short gradients of 27–41% 
acetonitrile (15 min) and 41–85% acetonitrile (5 min). After 5 min at 
85% acetonitrile, the gradient was reduced to 3% acetonitrile over 2 min 
and then allowed to equilibrate for 8 min. All acetonitrile solutions 
contained 0.1% formic acid. 
The DIA method comprised alternating mass spectrometry (MS) full 
scans spanning from 300 to 1650 m/z at 120,000 resolution, followed by 
37 DIA window scans at 30,000 resolution for peptide fragmentation 
with a variable width ranging from 300 to 1650 m/z. Normalized 
collision energy was adjusted to 28, with profile type spectra recording. 
The DIA liquid chromatography with tandem MS (LC − MS/MS) raw 
files were converted (HTRMS converter) and analyzed (Spectronaut 
version 11, Biognosys, Schlieren, Switzerland) as described (Lepper 
et al., 2018). An automatic calibration mode was chosen with precision 
indexed retention time (iRT) alignment enabled for the application of 
the nonlinear iRT calibration strategy. Peptides were identified by 
comparison with an in-house accumulated spectral library, which has 
been obtained from mouse brain samples measured on the same MS set- 
up with a data-dependent acquisition mode. Peptide identification was 
filtered for a false discovery rate (FDR) of 1%. Only proteotypic peptides 
were considered for quantification of proteins, applying MS2 area based 
summed precursor quantities. The data filtering function was set to q- 
value percentile mode applying a 50% setting, thus enabling a match 
between runs. This setting allows only peptide precursor signals passing 
the FDR threshold of 1% in over 50% of all samples to be further 
considered for identification and quantification, thus working towards a 
reduction of false positive identifications. The sum of abundances of all 
unique peptides per protein was log2 transformed and obtained values 
were compared between groups using an unpaired Student’s t-test with a 
significance level of p < 0.05. 
2.5. Pathway enrichment analysis 
Pathway enrichment analysis was completed using a publicly avail-
able pathway tool (Consensus PathDB over-representation tool, (Kam-
burov et al., 2009)). A background list was used, comprising of all 
identified proteins. Only pathways with both a p < 0.01 and at least two 
dysregulated proteins were considered. Only pathways reaching a q <
0.01 (=p-value corrected for multiple testing using the FDR method) 
were considered significant and discussed in this study. Protein abun-
dances of all proteins assigned to significantly changed pathways were 
visualized in a heat map. Individual fold changes for each animal were 
calculated by dividing their value against the wildtype group’s mean 
and log2 transforming this value. The resulting matrix was visualized 
using R software version 3.5.1 (Team, 2017) and “gplots” package 
(Warnes et al., 2016). 
2.6. Immunohistochemical staining of PPP1R1B (DARPP-32) 
In order to further confirm expression alterations of selected pro-
teins, brains from four-week-old wildtype and Dravet mice (n = 4 per 
group) were used for immunohistochemistry. Free-floating sections 
were washed in PBST (phosphate-buffered saline, 0.1% Tween 20) at 
room temperature and heat-induced epitope retrieval (HIER) was per-
formed at 80 ◦C for 30 min using sodium citrate buffer (pH 6.0). Sections 
were cooled down on ice and rinsed in PBST. Endogenous peroxidase 
was inhibited (3% H₂O₂ in TBS for 60 min). Slices were rinsed in PBST 
and a blocking step in 6% goat serum (60 min) was performed to prevent 
non-specific antibody binding. Sections were then incubated overnight 
at 4 ◦C with a monoclonal rabbit anti-DARPP32 primary antibody 
(Abcam, Berlin, Germany, Cat# ab40801, lot# GR3213231-3) diluted 
1:2500. The next day, sections were washed in PBST and incubated for 
60 min at room temperature with a secondary biotinylated goat anti- 
rabbit antibody (Vector laboratories, Cat# BA-1000, lot# 2F0430) 
diluted 1:1000. After washing steps in TBST, brain sections were incu-
bated at room temperature in VECTASTAIN ABC-Peroxidase Kit (Vector 
Laboratories Cat# PK-4000, RRID: AB_2336818, lot#2337238) for 60 
min, diluted 1:100. The slices were washed in PBS and stained using 
SIGMAFAST™ 3,3′-Diaminobenzidine tablets (Sigma-Aldrich, Darm-
stadt, Germany, Cat# D4418, lot# SLBR2966V) for 1 min. 
Brain sections were quickly rinsed in distilled H2O, washed in PBS, 
Fig. 1. A PCR genotyping for distinguishing Dravet mice with a Cre activated A1783V mutation (post Cre heterozygous) and wildtype mice. B Experimental timeline.  
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mounted on microscope glasses using PBST, and cover slipped with 
Entellan® (107960, Merck, Darmstadt, Germany). Negative controls 
were processed in parallel without the primary antibody. 
2.7. Immunohistochemical staining of HSD11B1 
The staining protocol for HSD11B1 was identical to the one 
described above (DARPP-32) with the following exceptions. Inhibition 
of endogenous peroxidase was done in 3% H₂O₂ in TBS for 15 min. A 
blocking step was performed with 1.5% goat serum for 120 min. The 
primary antibody was anti-HSD11B1 (Abcam, Berlin, Germany; Cat# 
ab39364, lot# GR3247054-7) diluted 1:200. Slices were stained in 
SIGMAFAST™ 3,3′-Diaminobenzidine solution for 100 s. 
2.8. Microscopy 
Bright field images were captured at 4×, 10× and 40× magnification 
with an Olympus BH2 microscope with a single chip charge-coupled 
device (CCD) color camera (Axiocam; Zeiss, Göttingen, Germany) and 
an AMD AthlonTM 64 processor based computer with an image capture 
interface card (Axiocam MR Interface Rev.A; Zeiss, Göttingen, 
Germany). 
2.9. Hyperthermia-induced seizures and threshold determination 
Hyperthermia-induced seizures were analyzed in mice at postnatal 
day 23, 25, and 32. Mice were transported to the laboratory 30 min prior 
to seizure induction. Temperature and light intensity in the laboratory 
were adjusted to 22 ± 2 ◦C and 600 lx. On all experimental days, tests 
began at 12 p.m. and the order of animals was randomized (randomizer. 
org). Observers were blinded to animal genotype as far as possible. At 
the early time point, blinding was difficult considering the obvious 
phenotype (lower body weight). The whole procedure was video 
recorded (Axis communications, Lund, Sweden). Body temperature was 
measured continuously with a RET-4 rectal probe (Physitemp, Clifton, 
New Jersey, USA), which was placed in warm saline solution (B. Braun 
Vet Care GmbH, Tuttlingern, Germany) before use. Subjects were placed 
in a plexiglass cylinder for 5 min to habituate to the environment and to 
record basal body temperature data. The IR lamp connected to the 
temperature controller (Physitemp, Clifton, New Jersey, USA) was then 
turned on to slowly increase the body temperature with a ramping rate 
of 0.5 ◦C per 2 min (Oakley et al., 2009). Heating was stopped imme-
diately when generalized tonic-clonic seizures were observed or when 
the body temperature reached 42 ◦C. Animals were allowed to cool 
down before returning them to their home cage. All equipment was 
cleaned with 70% ethanol between subjects (CLN, Langenbach, 
Germany). 
The severity of hyperthermia-induced seizures was assessed based on 
the Racine scoring system as follows: I (mouth and facial movements), II 
(head nodding), III (forelimb clonus), IV (rearing with forelimb clonic 
convulsions) and score V (generalized clonic convulsions followed by 
rearing and falling) (Racine, 1972). 
2.10. Spontaneous seizures 
Information about spontaneous seizure onset, frequency, duration, 
and severity score was obtained via continuous video monitoring from 
the second postnatal week for six weeks. Videos were carefully reviewed 
by experienced technicians at a maximum of 8× playback speed and all 
generalized seizures were documented. 
Two eight-month-old female mice (one wildtype, one Dravet) and 22 
twelve-week-old Dravet mice (11 males, 11 females) underwent survival 
surgery for telemetry (ETA-F10 or HD-X02, DSI, St. Paul, USA) and EEG 
electrode implantation. The order of animals was randomized (rando 
mizer.org). 30 min before anesthesia induction, mice received 1 mg/ 
kg meloxicam s.c. (Metacam®, Boehringer Ingelheim, Germany). For 
general anesthesia, mice received 400 mg/kg chloral hydrate i.p. (Carl 
Roth, Karlsruhe, Germany) (n = 2) or isoflurane (Isofluran CP®, Henry 
Schein Vet, Hamburg, Germany) with a concentration of 4% and 1.5% 
for anesthesia induction and maintenance, respectively (n = 22). The 
local anesthetic bupivacaine (0.5%; Jenapharm®, Mibe GmbH, Brehna, 
Germany) was applied subcutaneously to surgical areas affected by 
transmitter implants and leads placement. For intracranial electrode 
placement, bupivacaine with epinephrine (0.5% + 0.0005%; Jena-
pharm®, Mibe GmbH, Brehna, Germany) was applied subcutaneously. 
Firstly, the skin was opened in the dorsocaudal part of the scapula 
region for placing the telemetric transmitter subcutaneously. Mice were 
then fixed in a stereotactic frame and three screws were inserted into the 
skull. The negative EEG lead was connected to the screw over the cer-
ebellum. The positive EEG lead was connected to a bipolar Teflon- 
isolated stainless-steel electrode, which was implanted into the CA1 
region of the hippocampus (ap: − 2,00; lat: + 1,3; dv: − 1,6). The elec-
trode was fixed with Paladur (Heraeus®, Hanau, Germany). The skin 
over the skull was closed with absorbable sutures, while the initial cut 
for the transmitter placement was closed with tissue adhesive (Surgi-
bond®, Henry Schein Vet, Hamburg, Germany). 
As stated above, 22 animals were prepared for additional ECG 
analysis in the context of another study. Therefore, the negative ECG 
lead was fixed intramuscularly to the right pectoral muscle, whilst the 
positive ECG lead was fixed left of the xyphoid process prior to electrode 
implantation. Skin over the ECG connections was closed with absorbable 
sutures (Smi AG, St. Vith, Belgium). Animals were given oxygen until 
regaining consciousness. On the following day, mice received 1 mg/kg 
meloxicam s.c. Mice were allowed to recover for a full two weeks fol-
lowed by a two-week continuous recording phase. In parallel, animals 
were video monitored (Axis communications, Lund, Sweden) in order to 
confirm and analyze behavioral seizure activity. Data were acquired 
with Ponemah software (Ponemah R, v. 5.2.0, DSI, St. Paul, USA) and 
seizure activity was detected automatically (Neuroscore™ v. 3.0, DSI, 
St. Paul, USA). 
2.11. Behavioral characterization 
Following hyperthermia-induced seizures, all animals were tested in 
different behavioral paradigms except for one female Dravet mouse and 
one female wildtype mouse because of an age difference compared with 
the remaining animals. Thus, 22 Dravet mice (11 males; 11 females) and 
20 wildtype (11 males; 9 females) mice were used for behavioral 
assessments. 
One male Dravet mouse died following a spontaneous seizure and 
was therefore not exposed to the elevated plus maze and accelerated 
rotarod test. Data from one male Dravet mouse were not considered in 
the saccharin preference test due to leakage of one of the water bottles. 
During all behavioral paradigms, animals were single-housed as a pre-
supposition for the social interaction test. Social interaction was 
analyzed at an age of seven weeks and the order of the subsequent tests 
was as follows: open field test, saccharin preference test, elevated plus 
maze and accelerated rotarod test (Fig. 1B). The testing was completed 
until an age of ten weeks. The order of animals for each test was ran-
domized (randomizer.org). 
Nest-building activity as well as saccharin preference were assessed 
in the home cage. All other behavioral tests (social interaction, open 
field test, elevated plus maze, accelerated rotarod test) were completed 
in a test room (temperature 22 ± 2 ◦C, humidity 55 ± 5%) under 
different light conditions adjusted to the specific paradigm (stated 
below). All tests were carried out during morning hours (starting from 8 
a.m.). All behavioral test runs were documented by photographing (nest 
complexity) or video-recording (all other tests). 
2.12. Open field test 
The open field paradigm is widely used to assess exploratory 
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behavior and locomotion in an unfamiliar environment (Carola et al., 
2002). Mice were placed in the test room to habituate for 1 h prior to 
testing (lighting 15–20 lx). Two round shaped arenas (Ø 61 cm, height 
40 cm) were simultaneously used for the test. Time spent in three 
different zones (wall, middle and center) was analyzed with Ethovision 
8.5 software (EthoVision XT, RRID:SCR_000441). Each mouse was 
placed in one arena 10 cm away from and facing the wall. Locomotion 
was recorded for 30 min and rearing behavior was counted manually. 
After completing the test, mice were returned to their home cage. The 
arena was cleaned with 0.1% acetic acid between animals. 
2.13. Saccharin preference test 
The saccharin preference test was used to test anhedonia-associated 
behavior as one of the symptoms of depressive disorders (Klein et al., 
2015). The analysis was conducted during four consecutive 24-h-long 
periods in the home cage. Animals were provided with two water bot-
tles. First, both bottles were filled with water to determine water intake 
over 24 h. The bottle on the left side was then filled with a 0.1% 
saccharin solution. During the next day, both bottles were again filled 
with water. On the last day, the right bottle was filled with 0.1% 
saccharin solution in order to test for a potential side preference bias. 
Liquid consumption was measured after each period. 
2.14. Nest-building activity 
During postnatal week five, mice were individually placed into type 
III open cages. The following week, animals were provided with two new 
nestlets and nest complexity was assessed on a daily basis. Nests were 
photographed each morning. The images were later scored by an 
investigator blinded to group allocation. Nest complexity was ranked 
according to the scoring system developed by Jirkof and colleagues as 
follows (Jirkof et al., 2013): score 0 = nestlet intact, possibly carried 
around the cage; score 1 = nestlet is poorly manipulated with more than 
80% of the nestlet intact; score 3 = evident nest site with most of shreds 
in the nest site, less than 80% nestlet material intact, hollow in bedding 
and mice begin to build walls; score 4 = flat nest, hollow in bedding, 
walls are higher than mice and encasing the nest less than 50%; score 5 
= complex, bowl-shaped nest with walls higher than mice and encasing 
the nest more than 50%. 
2.15. Social interaction test 
The social interaction test was performed to assess autism-associated 
behavioral patterns and affinity towards interaction with another 
mouse. Mice were single-housed in type III open cages for two weeks 
prior to testing. On the first two days, animals were transported to the 
test room (lighting 15–20 lx) and placed in an empty type III open cage 
for 10 min to habituate. On the test day, animals were transported to the 
test room 30 min prior to testing. Two mice of the same sex, same ge-
notype and approximately same weight were then simultaneously 
placed in an empty cage and left for 10 min. Active and passive social 
interaction were measured with a stopwatch by an observer blinded to 
animal genotype and sex. The cage was cleaned with 0.1% acetic acid 
between subjects. Sniffing, grooming or following the partner as well as 
aggressive behavior were considered as active social interaction. Laying 
or sitting next to each other without any interaction was classified as 
passive social interaction (Holter et al., 2015). 
2.16. Elevated plus maze 
The elevated plus maze is generally used to assess anxiety-like 
behavior in rodents (Ben-Hamo et al., 2016). Mice were placed in the 
test room for 1 h prior to the experiment. The maze comprised of two 
open arms (40 cm long and 10 cm wide) and two closed arms (same 
dimensions with walls 15 cm high). The plus maze was elevated 68 cm 
above the floor. Light intensity was set to approximately 200 lx in the 
open and 60 lx in the closed arms. Animals were placed in the center of 
the maze facing the open arm. A five-minute-long trial was recorded 
with Ethovision XT for each animal. Head-dipping and stretching 
behavior (exploring the open arms with the head while the body stays in 
the closed arms or center part of the maze) were recorded manually by 
observers blinded to animal group allocation. The maze was cleaned 
with 0.1% acetic acid between animals. 
2.17. Accelerated rotarod test 
The accelerated rotarod test is widely used to evaluate motor per-
formance in mice (Shiotsuki et al., 2010). Mice were placed in the test 
room for 1 h prior to assessment to habituate (15–20 lx). A rotarod 
apparatus (Ugo Basile 47,600, Varese, Italy) was used to assess the an-
imals’ motor coordination. The rotation accelerated from 4 to 40 rpm 
over 5 min. Each animal was subjected to four consecutive trials with 
approximately 2 min break for cleaning the rod (0.1% acetic acid). 
Testing was carried out on three subsequent days, the first for training 
and the others for testing. Male animals were always tested before fe-
males. Passive rotations, time remaining on rod and current rod speed 
were recorded. 
2.18. Statistical analysis 
Statistical analysis was performed with R version 3.5.1. GraphPad 
Prism (Version 5.04 and 6.01, GraphPad, USA) was used for data visu-
alization, except for heat maps, which were visualized with R, and Venn 
diagrams, visualized with an online tool (http://bioinformatics.psb. 
ugent.be/webtools/Venn/). The functional and molecular annotation 
of differentially expressed proteins was prepared using a Panther clas-
sification system (http://pantherdb.org/). Fig. 8 was prepared using a 
pathway downloaded from KEGG PATHWAY Database (https://www. 
kegg.jp/kegg/pathway.html). A Spearman correlation matrix was 
calculated using R version 3.5.2. The significance level for correlation 
analysis was set at < − 0.5 or >0.5. Animals with missing data were not 
considered for the respective correlation analysis. 
All data were expressed as mean ± SEM with the exception of nest 
complexity data, for which the median is illustrated in the respective 
graph. All results were first checked for possible batch effects. If present, 
batch effects were considered in the statistical analysis. 
Two-tailed unpaired t-tests were used for comparison between 
experimental and control groups where indicated. Two-, three-, four- 
and five-way ANOVAs were used to test the effects of genotype, sex, 
time, batch and their interaction where appropriate. Comparisons, 
which included multiple measurements, were tested using repeated 
measures ANOVA. ANOVA tests were followed by a Bonferroni post-hoc 
test. A two-tailed Mann-Whitney non-parametric test was used for 
analyzing nest complexity scores. The significance level was set at p <
0.05 for all tests. 
2.19. Data availability 
The raw data sheet with individual protein abundances, which sup-
ports the findings of this study, is provided in Appendix A (Dataset). A 
complete list of abbreviations of significantly regulated proteins 
mentioned in the manuscript sorted by their function is provided in 
Appendix A (Supplementary Material, Table A.1). 
3. Results 
3.1. Breeding pattern and outcome 
Twenty-three female mice heterozygous for Cre recombinase 
(129S1/Sv-Hprttm1(CAG-cre)Mnn/J) were bred with 21 conditional knock- 
in male mice with floxed Scn1a-1783V (B6(Cg)-Scn1atm1.1Dsf/J) in 
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pairwise and trio matings split into two different batches. Eighteen of 
them delivered litters with a total of 38 heterozygous mutant mice 
(Dravet mice) and 41 wildtype littermates. The sex ratio in the offspring 
was almost balanced with 38 males (19 Dravet; 19 WT) and 41 females 
(18 Dravet; 23 WT). Due to the 40% mortality rate around the time of 
weaning, 15 Dravet mice were lost. The remaining 23 Dravet mice and 
randomly selected 21 wildtype mice (randomizer.org) were used for 
model characterization. 
3.2. General condition, body weight development, seizure thresholds and 
spontaneous seizures 
The body weight of Dravet mice proved to be significantly lower at 
the time point of weaning. However, following weaning, affected ani-
mals showed a good development of body conditioning scores finally 
reaching a comparable body weight to wildtype mice (Fig. 2A). 
In response to hyperthermia induction, all Dravet mice exhibited 
generalized tonic-clonic seizures on all three testing days. In contrast, 
their wildtype littermates did not exhibit motor seizure activity despite 
increasing their body temperature to at least 41 ◦C. 
The number of Dravet mice showing running and bouncing behavior 
increased with repeated hyperthermia induction reaching 18/23 ani-
mals on P32. The average threshold temperature for seizure induction 
was 39.7 ± 0.9 ◦C at P23, 39.7 ± 0.6 ◦C at P25, and 39.1 ± 0.5 ◦C at P32 
(mean ± SD, Fig. 2B). Seizure duration significantly increased with 
subsequent stimulations (Fig. 2C). No differences were observed when 
comparing female and male mice. 
Video monitoring of experimental animals in their home cages 
demonstrated the development of spontaneous motor seizures at P16. 
The seizures observed included generalized tonic-clonic seizures, 
sometimes associated with running and bouncing indicating seizure 
spread towards the brain stem. In addition, prolonged phases with 
behavioral arrest, immobility, and lack of responsiveness to external 
stimuli were observed. Between P20 and P23 several Dravet mice died. 
In several instances, video monitoring indicated that the death was 
directly associated with a generalized seizure. Considering data and 
findings from a more detailed analysis of seizure–associated death in 
other mouse models with Scna1a deficiency (Kalume, 2013; Teran et al., 
2019) it is not unlikely that the death observed in mice with the 
A1783V-Scn1a mutation may be related to SUDEP or probable SUDEP. 
However, future investigations are necessary to confirm this 
assumption. 
The total mortality rate reached 40%. The remaining 23 Dravet an-
imals were used for behavioral characterization. Seizure-associated 
death was rarely observed in older animals. Only one animal was 
found dead in its cage following the fourth postnatal week. 
To further confirm spontaneous seizure activity, telemetric EEG re-
cordings were performed with simultaneous video recordings in an adult 
Fig. 2. Body weight, spontaneous and 
hyperthermia-induced seizures. A Body 
weight development following weaning. 
Body weight in animals with a Dravet ge-
notype (males n = 11; females n = 11) was 
significantly lower in the early phase 
following weaning (females until P25, males 
until P41) as compared to wildtype mice 
(males n = 11, females n = 9) (Unpaired t- 
test; *p < 0.05 males, #p < 0.05 females, 
mean ± SEM). B Seizure threshold tempera-
ture at P23, P25, and P32. The threshold 
significantly decreased on P32 compared to 
previous testing. C Total duration of 
hyperthermia-induced seizure activity, 
calculated as the sum of all motor seizure 
periods occurring immediately following 
stimulation. The duration significantly 
increased with repeated stimulations. B–C 
Data are from 11 male and 12 female ani-
mals with a Dravet genotype (Two-way RM 
ANOVA, Bonferroni post hoc; *p < 0.05, 
mean ± SEM). D Representative EEG 
recording of a generalized tonic-clonic 
seizure (Racine score V, followed by 
running und bouncing) in an adult female 
mouse.   
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female Dravet and female wildtype mouse. During the one-week 
recording, the Dravet mouse exhibited multiple generalized tonic- 
clonic seizures often followed by running and bouncing. Assessment of 
the EEG recordings confirmed electrographic seizure activity with high 
amplitude spiking over 500 μV (Fig. 2D). In the wildtype mouse, no 
evidence was obtained for electrographic seizure events. 
Additional recordings in a group of three-month old Dravet mice 
confirmed a high penetrance of the epilepsy phenotype with multiple 
generalized tonic-clonic seizures in 19/22 mice. On average, mice 
experienced seven seizures per week (range: two to 16; data not shown). 
Seizures frequently occurred in clusters with animals often exhibiting 
seizures on only two subsequent days per week (range: one to four, data 
not shown). The average seizure duration was 50.19 s (data not shown). 
3.3. Phenotype: behavioral alterations 
In the open field paradigm, hyperlocomotion was evident in male 
and female Dravet mice. Throughout the 30-min test, the total distance 
moved and the rearing frequency was significantly greater in Dravet 
mice as compared to wildtype animals (Fig. 3A-B). Moreover, immo-
bility time proved to be shorter in Dravet mice (data not shown). 
Additionally, thigmotaxis proved to be increased in Dravet mice with 
more time spent in the wall zone. Time spent in the other zones (middle 
and center) was not affected by the genotype (Fig. A.1C). 
Regardless of genotype, a preference for saccharin solution over 
water was observed. However, the amount of saccharin consumed by 
wildtype mice exceeded that of mice with the Dravet genotype. In line 
with this finding, the percentage of consumed saccharin solution was 
reduced in Dravet mice (mean ± SD: Dravet mice 64.07 ± 8.64%; 
wildtype mice 70.38 ± 6.41%) (Fig. 3E). 
Interestingly, when saccharin consumption was compared between 
the first and the second exposure, Dravet mice consumed similar 
amounts whereas wildtype mice consumed more saccharin solution on 
the subsequent exposure (Fig. 3C–D). Findings were comparable in male 
and female mice. 
Nest-building behavior, a non-essential activity, demonstrated a 
poorer performance in mice with a Dravet genotype (Fig. 3F). 
When analyzing social interaction following a period of social 
isolation in single-housing, all Dravet mice spent more time engaged in 
active and less time in passive social interaction when compared to 
wildtype littermates (Fig. A.1A–B). 
In the elevated plus maze, the total time spend on open or closed 
arms proved to be reduced in Dravet mice versus wildtype mice 
(Fig. A.2A). When analyzing the time spend on the different types of 
Fig. 3. Open field test, saccharin preference 
and nest-building behavior. A Distance 
moved in the open field test over 30 min, 
divided into mean intervals of 5 min. The 
total distance moved of Dravet mice signifi-
cantly exceeded that of wildtype mice. B 
Rearing frequency. Dravet mice exhibited 
more frequent rearing positions than wild-
type mice. A–B Data are from 22 animals 
with a Dravet genotype and 20 wildtype 
animals (Three-way RM ANOVA, Bonferroni 
post hoc; *p < 0.05, mean ± SEM). C–D 
Water (white column) or saccharin solution 
(black column) consumption per 24 h. Both 
Dravet and wildtype mice preferred 
saccharin solution over water, independent 
of a side preference. E Total saccharin solu-
tion consumption over both days. Dravet 
mice consumed significantly less saccharin 
solution as compared to wildtype mice. C–E 
Data shown are from 21 animals with a 
Dravet genotype and 20 wildtype animals 
(Three-way ANOVA, Bonferroni post hoc; *p 
< 0.05, mean ± SEM). F Nest complexity 
score over seven days. As shown in the 
graph, nests of Dravet mice (n = 22) received 
lower scores as compared to those from 
wildtype mice (n = 20) (Mann-Whitney non- 
parametric test; *p < 0.05, median).   
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arms, it became evident that Dravet mice spent more time in aversive 
parts, i.e. the open arms of the maze, and less time in the closed arms of 
the maze (Fig. A.2B–C). In addition, a higher frequency of head dips and 
a reduction in stretching behavior was evident in all Dravet mice 
(Fig. A.2D–E). Sex differences were not observed. 
We applied the accelerated rotarod test to address disturbances in 
motor coordination. During habituation, animals from both groups 
showed a “learning” curve with an improvement in performance with 
subsequent trials. Thereby, it was evident that this was related to an 
increased focus of the animals on the task. When compared to wildtype 
mice, Dravet mice remained on the rod for longer. Additionally, females 
performed better than males in both the control and experimental 
groups (Fig. A.1D–F). 
The Spearman correlation coefficients between selected parameters 
were calculated. Open field test variables including total distance moved 
showed a significant correlation (all p < 0.001) with social interaction 
(active r = 0.69, passive r = − 0.52), nest complexity score (r = − 0.57), 
time spent in aversive parts (r = 0.58), and number of head-dips in the 
elevated plus maze test (r = 0.76). 
3.4. Proteomic profiling 
Proteomic profiling identified over 4000 different proteins in the 
mouse hippocampus samples. Comparison of protein abundance 
revealed that, as a consequence of the genetic Scn1a deficiency, signif-
icant alterations in the expression of 205 and 881 proteins were 
observed in two- and four-week-old Dravet mice as compared to wild-
type littermates, respectively (unpaired t-test, p < 0.05, Fig. 4A). While 
the majority of these differentially expressed proteins were up-regulated 
at the early time point, more proteins were down-regulated at the later 
time point (Fig. 4B). As the down-regulation of proteins can be a general 
consequence of neuronal damage and cell loss, expression of the 
neuronal marker NeuN was assessed. It remained at control levels for 
both time points (data not shown). Moreover, we confirmed that the 
heterozygous loss-of-function Scn1a mutation did not result in changes 
in NaV1.1 protein abundance regardless of the time point (data not 
shown). Although changes in protein expression as a consequence of a 
missense mutation are not necessarily expected, this finding is of rele-
vance for model characterization as both enhanced degradation of a 
non-functional protein as well as a compensatory expressional up- 
regulation are possible. 
A direct comparison of the datasets from both time points revealed 
an overlap of 67 differentially expressed proteins (Fig. 4A). Most of the 
proteins maintained the direction of change. However, some proteins 
were down-regulated at the earlier time point but later showed an 
overexpression or vice versa (Fig. 4C). 
While a more pronounced proteome alteration was evident at the 
later time point, the functional annotation of differentially expressed 
proteins from both time points revealed some similarities in the quali-
tative pattern of protein regulation with a comparable distribution of 
regulated proteins to different functional groups (Fig. 5A). 
The majority of regulated proteins were classified as metabolite 
Fig. 4. Differentially expressed proteins in Dravet mice. A Overlap of differentially expressed proteins in two- and four-week-old Dravet mice illustrated by a Venn 
diagram. B Total number of differentially expressed proteins in two- and four-week-old Dravet mice. C The heat map illustrates the fold change in protein level in 
relation to the mean of the wildtype group in two- and four-week-old Dravet mice. The respective color key is provided beneath the heat map. 
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interconversion enzymes, protein modifying enzymes, protein-binding 
activity modulator and translational proteins at the earlier time point, 
and metabolite interconversion enzymes, protein modifying enzymes 
and transporters at the later time point. Regarding the molecular func-
tion of dysregulated proteins, again, a more pronounced protein regu-
lation was evident at the later time point (Fig. 5B). Proteins associated 
with catalytic activity and binding exhibited the strongest regulation at 
both time points. 
3.5. Differential protein expression – early time point 
Proteomic profiling in Dravet mice prior to the occurrence of first 
spontaneous seizures and epilepsy manifestation can provide informa-
tion about the process of epileptogenesis as a direct consequence of 
Scn1a genetic deficiency. As mentioned above, a pathway enrichment 
analysis was completed to obtain general information about the regu-
lation pattern concerning function and neurobiological significance. 
Pathway enrichment analysis did not identify any significantly regulated 
pathway (q < 0.01). 
When considering significantly regulated individual proteins in 
Dravet mice (unpaired t-test, p < 0.05), the most prominent down- 
regulation became evident for Ras-specific guanine nucleotide 
releasing factor 1 (RASGRF1). RASGRF1 is a member of the Ras GTP 
protein family, which plays a role in synaptic plasticity (Brambilla et al., 
1997). RASGRF1 is associated with NMDA receptors (Krapivinsky et al., 
2003) and its regulation or dysfunction has been discussed in the context 
of epileptogenesis and epilepsy manifestation (Chen et al., 2018; Tonini 
et al., 2001; Vlaskamp et al., 2019). 
Considering the more modest regulation of most other significantly 
regulated proteins, we will highlight a selection based on their putative 
functional relevance and a minimum change of at least 15% compared to 
expression rates in wildtype mice (Fig. 6A). 
CAMK2A encodes the alpha subunit of calcium/calmodulin- 
dependent protein kinase and represents a key player in synaptic plas-
ticity (Lisman et al., 2002). Two-week-old mice exhibited a reduced 
expression rate that persisted at the four-week time point. 
Additionally, Dravet mice showed an up-regulation of VEGF receptor 
KDR (VEGFR2). It is linked with tight junction disassembly and blood- 
brain barrier dysfunction, which in turn can contribute to epilepto-
genesis (Morin-Brureau et al., 2012). 
Cytidine triphosphate synthetase 2 (CTPS2) is a protein mediating 
CTP synthesis from UTP, a process that is linked with glutamine 
deamination to glutamate (Kassel et al., 2010). In two-week-old Dravet 
mice, we obtained evidence for an increased expression level of CTPS2. 
3.6. Differential protein expression – later time point 
Proteomic profiling following epilepsy manifestation capturing 
direct and indirect consequences of Scn1a deficiency in Dravet mice 
revealed 881 regulated proteins (unpaired t-test, p < 0.05) and 42 
regulated pathways (q < 0.01, Table 1). A heat map, which illustrates 
the level of individual protein change in relation to the mean of the 
wildtype group, is presented in Fig. 6B. 
Pathways functionally linked to synaptic transmission dominated the 
list of significantly enriched pathways, in total comprising five pathways 
associated with general synaptic function and its regulation (Neuro-
transmitter receptors and postsynaptic signal transmission; Transmission 
across Chemical Synapses; Protein-protein interactions at synapses; Synaptic 
adhesion-like molecules; and Neurexins and neuroligins with corresponding 
q-values 4.14e− 05; 4.14e− 05; 2.33e− 04; 0.002; 0.006). The list of differ-
entially expressed proteins linked with these pathways comprised 68 
proteins. Several of these proteins proved to be down-regulated as a 
consequence of the genetic deficiency. These include synaptic adhesion- 
like molecules such as neurexins and neuroligins (Fig. 6B: NLGN2, 
NLGN3), which mediate trans-synaptic signaling and facilitate the pro-
cessing of complex signals in neuronal networks (Südhof, 2008), as well 
as postsynaptic density (PSD) proteins including proteins of the 
membrane-associated guanylate kinase protein family (Fig. 6B-a), and 
scaffolding proteins (Fig. 6B-b). Moreover, these pathways included 
proteins associated with synaptic vesicles (Fig. 6B-c). 
Proteins linked with ion channel function showed a complex regu-
lation pattern in Dravet mice. The abundance of voltage-gated calcium 
channels (Fig. 6B-d), voltage-gated potassium channels (Fig. 6B-e) and 
two inward-rectifier potassium channels (Fig. 6B-f) was reduced in 
Dravet mice. Another inward-rectifier potassium channel (Fig. 6B: 
KCNJ10) was up-regulated in Dravet mice. 
Fig. 5. Classification of differently expressed proteins. Functional (A) and molecular (B) annotation of differentially expressed proteins in two- and four-week-old 
Dravet mice. 
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Interestingly, several neurotransmitter receptor proteins exhibited a 
differential expression pattern in Dravet mice. The list of these proteins 
was dominated by glutamatergic receptor proteins (Fig. 6B-g), which 
were all expressed at lower levels in Dravet mice. In addition, a change 
in expression of three GABAA receptor subunits (Fig. 6B-h) and of two 
GABAB receptor subunits (Fig. 6B-i) was evident with an induction of 
GABRA1 and GABBR1, and a down-regulation of GABRB1, GABRB3 and 
GABBR2. 
In the context of neurotransmitter signaling, it is of additional in-
terest that four pathways involved in glutamatergic signaling, specif-
ically AMPA and NMDA receptor activation, binding, and synapses were 
regulated in Dravet mice (Glutamatergic synapse; Unblocking of NMDA 
receptor, glutamate binding and activation; Trafficking of AMPA receptors; 
Glutamate binding, activation of AMPA receptors and synaptic plasticity 
with q-values 1.4e− 04; 0.001; 0.002; 0.002, respectively). Thereby, 
Dravet mice exhibited a reduced expression of iono- and metabotropic 
glutamate receptors, glutamate transporters (Fig. 6B: EAAT1, EAAT2), 
and glutamine synthetase (Fig. 6B: GLUL). 
Pathway enrichment analysis also revealed an overrepresentation of 
proteins functionally associated with dopaminergic synapse function (q 
= 0.002, Fig. 6B-j). The changes in the pathway were dominated by 
alterations in the expression of proteins regulating dopamine meta-
bolism or stabilizing D2 and D3 receptors on plasma membranes with 
MAOA up-regulated and MAOB, EPB41L1, EPB41L3 down-regulated. In 
four-week-old Dravet mice, reduced expression levels were also evident 
for GNG7, the G protein responsible for A2A adenosine or D1 dopamine 
receptor-induced neuroprotective responses (Schwindinger et al., 2012). 
Another protein that plays a role in synaptic plasticity and can be 
modulated by both dopaminergic D1 and glutamatergic NMDA re-
ceptors is the neuronal phosphoprotein PPP1R1B. Our data set revealed 
an overexpression in the hippocampus of four-week-old Dravet mice, 
which was further confirmed by immunohistochemistry. All Dravet 
animals demonstrated a marked hippocampal overexpression, particu-
larly evident in CA1 stratum pyramidale neurons (Fig. 7A–B). 
In four-week-old mice, pathway enrichment analysis also demon-
strated an over-representation of proteins functionally linked to calcium 
signaling (q = 1.4e− 04). Individual protein changes pointed to a down- 
regulation of calcium channel proteins and calcium transporters 
(Fig. 6B-k). Calcium/calmodulin-dependent protein kinases (Fig. 6B-l) 
were reduced in Dravet mice. 
The list of regulated pathways also included a pathway involved in 
secondary cell signaling (Phosphatidylinositol signaling pathway, q =
0.008). Moreover, an over-representation of proteins linked with the 
Nitric oxide (NO) signaling pathway (q = 0.005) was evident. In this 
context, the increased level of nitric oxide synthase, the main enzyme 
responsible for NO synthesis from L-arginine (Knowles et al., 1994), is of 
interest. 
In addition to pathway enrichment analysis, we also identified the 
proteins with the most prominent regulation pattern. The strongest up- 
regulation was evident for the intermediate filament proteins glial 
fibrillary acidic protein (GFAP) and vimentin. The expression of both 
proteins was elevated at least two-fold in Dravet mice. 
The proteins with the strongest down-regulation were TRIM32 and 
HSD11B1. Proteomic profiling pointed to a reduction in HSD11B1 
expression in Dravet mice, with a two times lower abundance than in 
wildtype mice. This finding was further confirmed by immunohisto-
chemistry. An apparent down-regulation of the protein was evident in 
the hippocampus with the most obvious reduction in the hilus 
(Fig. 7C–D). 
4. Discussion 
The large-scale proteomic analysis in a novel conditional mouse 
model of Dravet syndrome with Scn1a genetic deficiency provided 
comprehensive information about the molecular alterations character-
izing different disease phases. Respective information about the prote-
omic signature of Dravet syndrome suggests possible pathophysiological 
mechanisms beyond Scn1a haploinsufficiency that may be involved in 
epileptogenesis and ictogenesis in Dravet mice. 
As a basis for the proteomic analysis, we initially aimed to validate 
the novel conditional knock-in mouse model of Dravet syndrome with a 
heterozygous Scn1a-A1783V mutation. A model with this mutation has 
previously been generated on a pure C57BL/6J background (Ricobaraza 
et al., 2019) and a mixed 90:10 C57BL/6J and 129S6 background (F1 
hybrid of 100% C57BL/6J and 85:15 C57BL/6J:129S6 background) 
(Kuo et al., 2019) resulting in a more severe phenotype and higher 
mortality rate. Here, we characterized the model bred on a mixed 50:50 
(F1 hybrid) C57BL/6J and 129S1 background with an Hprt promoter 
mediated neuronal knock-in. We confirmed the development of spon-
taneous seizures and an increased susceptibility to hyperthermia- 
induced seizures and demonstrated a mortality rate of 40%. Besides 
the seizure phenotype, we also observed behavioral alterations domi-
nated by hyperactivity, which seem to reflect hyperactivity and atten-
tion deficits as common behavioral symptoms in patients with Dravet 
syndrome (Battaglia et al., 2016; Besag, 2004; Dravet, 2011). 
When compared to other animal models of Dravet syndrome with a 
heterozygous Scn1a mutation, our model showed a similar age for onset 
of spontaneous seizures, increased susceptibility to thermally provoked 
seizures and notable hyperactivity. The SUDEP rate was relatively low 
compared to other models and occurred almost exclusively within a 
short time window (Table A.2). With the approaches used in this study, 
we failed to detect motor and social deficits in Dravet mice, which have 
been reported in selected mouse models (Table A.2). However, an 
improved performance on the accelerated rotarod test was also found in 
another mouse model (Ito et al., 2013), suggesting the test itself may not 
be appropriate to assess the Dravet-associated alterations in motor 
function and coordination. In this context, it is of interest that we 
confirmed alterations in gait in a follow-up study with a catwalk test and 
a detailed assessment of gait (Miljanovic et al., accepted). 
To our knowledge, this is the first report of anhedonia-associated 
behavior in a Dravet mouse model indicating that SCN1A deficiency 
may have an impact on the affective state and may predispose to 
depression. In the context of behavioral tests, it is important to consider 
that we cannot exclude the possibility that behavioral patterns might 
have been influenced by sensory deficits. For instance, an altered taste 
preference may affect saccharin preference or an impaired vision may 
affect behavior in the elevated-plus maze. 
Information about body weight development has not been provided 
for all Dravet mouse models. As such, for several models, it is unclear 
whether there was no delay or whether body weight development was 
Fig. 6. Expression analysis of proteins significantly regulated in Dravet mice before and following epilepsy manifestation. A Expression analysis of proteins 
significantly regulated in Dravet mice prior to epilepsy manifestation with a minimum change of at least 15% compared to expression rates in wildtype mice. The R 
package ‘gplots’ was used to generate heat maps. The heat map illustrates the fold change in protein level in relation to the mean of the wildtype group and the 
respective color key is provided next to the heat map. B Expression analysis of proteins linked to all significantly enriched pathways in Dravet mice following epilepsy 
manifestation. The R package ‘gplots’ was used to generate heat maps. The heat map illustrates the fold change in protein level in relation to the mean of the wildtype 
group and the respective color key is given underneath the heat map. a PSD membrane-associated guanylate kinase protein family, b PSD scaffolding proteins, c 
proteins associated with synaptic vesicles, d voltage-gated calcium channel proteins, e voltage-gated potassium channel proteins, f inward-rectifier potassium channel 
proteins, g glutamatergic receptor proteins, h GABAA receptor subunits, i GABAB receptor subunits, j proteins functionally associated with dopaminergic (DAergic) 
synapse function, k calcium transporter proteins, l calcium/calmodulin-dependent protein kinases. (Blue cell color indicates an up-regulation, while red cell color 
stands for a down-regulation). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
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0.000 0.000 Amphetamine addiction - 
Homo sapiens (human) 
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GLUA1; GLUA4; GLUL; 














0.000 0.000 Protein-protein 
interactions at synapses 
Reactome GLUA3; GLUA1; 
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FLOT1; FLOT2 
0.000 0.001 Unblocking of NMDA 
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binding and activation 
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not assessed and documented. The impact of the genetic deficiency on 
body weight development has only been reported in selected Dravet 
mouse models with heterozygous (Ricobaraza et al., 2019) and homo-
zygous mutations (Martin et al., 2010; Ogiwara et al., 2007). In line with 
these reports, we observed a transient delay in body weight around 
weaning with animals catching up within five (females) or 20 (males) 
days following weaning. 
4.1. GABAergic, glutamatergic, and dopaminergic neurotransmission 
Loss of function of sodium channel subunits encoded by the SCN1A 
gene in GABAergic interneurons is considered as the main source of 
hyperexcitability and ictogenesis in Dravet patients (Brunklaus and 
Zuberi, 2014; Catterall, 2018) and animals carrying the respective mu-
tation (Almog et al., 2019; Kalume et al., 2015; Mantegazza and Broc-
coli, 2019; Mistry et al., 2014; Rubinstein et al., 2015; Salgueiro-Pereira 
et al., 2019; Tai et al., 2014; Tsai et al., 2015; Yu et al., 2006). However, 
an impact of cellular consequences in excitatory neurons on seizure 
susceptibility has also been suggested based on experimental findings. 
For instance, hyperexcitability of dissociated hippocampal pyramidal 
neurons (Mistry et al., 2014) and granule cells in the dentate gyrus (Tsai 
et al., 2015) in the period of chronic epilepsy may promote life- 
threatening seizures, known to exacerbate the mice phenotype (Dut-
ton et al., 2017; Salgueiro-Pereira et al., 2019). On the other hand, 
Ogiwara and colleagues demonstrated that Scn1a haploinsufficiency in 
hippocampal excitatory neurons can ameliorate seizures in Dravet mice 
(Ogiwara et al., 2013). Interestingly, Almog and colleagues showed how 
the hyperexcitability of CA1 pyramidal neurons during the pre-epileptic 
state can switch to hypoexcitability during the epileptic state in Dravet 
mice suggesting a role for these neurons in seizure propagation (Almog 
et al., 2019). 
Altogether, these data suggest that both inhibitory and excitatory 
neurotransmission may be directly and indirectly affected by NaV1.1 
dysfunction. Interestingly, the proteomic data suggest differential 
expression of multiple proteins linked with inhibitory and excitatory 
neurotransmission in Scn1a+/− mice. 
With changes in the abundance of various GABAA and GABAB re-
ceptor subunits, our findings indicate that signaling via both GABA re-
ceptor systems can be altered as a consequence of a Scn1a genetic 
deficiency with potential consequences for phasic and tonic inhibition. It 
should therefore be considered that both an up- and a down-regulation 
was observed for the different receptor subunits. 
Concerning glutamatergic signaling, proteomic patterns in Dravet 
mice revealed a comprehensive down-regulation of subunits of NMDA, 
AMPA, and kainate glutamate receptors. In this context, it is of addi-
tional interest that several proteins linked with NMDA receptor function 





Pathway Source Overlap members 
GLUN2A; CAMK2B; 
NEFL; GLUN1 
0.000 0.002 Dopaminergic synapse - 
Homo sapiens (human) 
KEGG GLUA2; GLUA3; 















0.000 0.002 Trafficking of AMPA 
receptors 
Reactome EPB41L1; CACNG8; 







0.000 0.002 Glutamate binding. 
Activation of AMPA 
receptors and synaptic 
plasticity 
Reactome EPB41L1; CACNG8; 







0.000 0.002 Synaptic adhesion-like 
molecules 





0.000 0.003 Neuroactive ligand- 
receptor interaction - 
Homo sapiens (human) 









0.000 0.003 Amyotrophic lateral 
sclerosis (ALS) - Homo 
sapiens (human) 
KEGG GPX1; TOMM40L; 







0.000 0.005 Nitric oxide signaling 
pathway 













SHANK1; SYT1; SYT7; 
GLUN2B; GLUN2A 
0.000 0.008 Cocaine addiction - Homo 
sapiens (human) 
KEGG PPP1R1B; DLG4; 
GLUA2; GLUN2B; 
MAOB; MAOA; 
GLUN2A; GLUN1;  





Pathway Source Overlap members 
MGLUR3; GNAI3; 
MGLUR2; GNAI1 
0.000 0.008 Fmlp induced chemokine 
gene expression in hmc-1 
cells 






0.000 0.008 Phosphatidylinositol 
signaling system - Homo 
sapiens (human) 
KEGG OCRL; PLCB1; PRKCB; 
PI4KA; INPPL1; 
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in the post-synaptic density showed a decreased abundance in Dravet 
mice. In addition, SYNGAP1, a post-synaptic density protein that 
negatively modulates trafficking of AMPA receptors to the membrane 
(Jeyabalan and Clement, 2016), also exhibited a dysregulation in the 
hippocampus as a consequence of the Scn1a deficiency. 
Concerning the expression patterns of metabotropic glutamate re-
ceptor proteins, it should be considered that some of these receptors 
have a negative feedback function that limits excessive glutamate 
secretion (Dedeurwaerdere et al., 2015). Along this line, the reduced 
expression of the class two metabotropic glutamate receptor proteins 
mGluR2 and mGluR3 in Dravet mice might be of functional interest. 
In addition to alterations in receptor proteins and PSD proteins, the 
lowered abundance of glutamine synthase and higher abundance of 
CTPS2, which contributes to deamination of glutamine to glutamate 
(Kassel et al., 2010), may imply that changes occur in glutamate 
metabolism. 
Taken together our proteomic data set suggests that complex alter-
ations occur affecting GABA and glutamatergic signaling. The direction 
of the alterations seems to suggest that some of these changes may 
contribute to hyperexcitability, whereas others may rather reflect 
compensatory mechanisms. Further research is necessary to explore the 
potential functional consequences. 
Depending on the receptor subtype, dopaminergic signaling can 
affect seizure thresholds (Bozzi and Borrelli, 2013). Altered abundance 
of the dopamine metabolizing enzymes MAOA and MAOB, of PPP1R1B a 
downstream effector protein of D1 receptors (Bozzi and Borrelli, 2013; 
O’Sullivan et al., 2008), and of proteins stabilizing D2 and D3 receptors, 
suggests that it may also be of interest to assess dopamine concentrations 
in the brain of Dravet mice. 
4.2. Voltage-gated ion channels 
Voltage-gated ion channels affect neuronal excitability in different 
subcellular localizations therefore serving as important target sites for 
different antiseizure drugs (Sills and Rogawski, 2020). 
At the presynaptic level, P/Q- and N-type calcium channels represent 
important regulators of neurotransmitter release (Kassel et al., 2010). 
Thus, the extensive down-regulation of voltage-gated calcium channel 
subunits may constitute a compensatory mechanism counteracting the 
increased neuronal excitability characterizing Dravet syndrome. In this 
context, it is of additional interest that various calcium/calmodulin- 
dependent protein kinase (CaMK) subtypes proved to be reduced in 
hippocampal tissue from Dravet mice. CaMKs are important regulators 
that translate intracellular calcium concentrations into phosphorylation 
patterns with functional consequences for the targeted proteins (Swulius 
and Waxham, 2008). 
Several potassium channels regulate outward potassium currents, 
thereby affecting membrane polarization and neuronal excitability 
(Villa and Combi, 2016). Proteomic data revealed a reduction of three 
potassium channel subunits (Kv1.2, Kv2.1 and Kv4.2) that attenuate 
back-propagating action potentials and prevent highly repetitive 
neuronal firing as one of the pathophysiological hallmarks of epileptic 
seizures (Niday and Tzingounis, 2018). 
In summary, various changes in voltage-gated ion channel proteins 
occur in the Dravet mouse model. The reduction of calcium channel 
subunits and of potassium channel subunits may have contrasting con-
sequences, which should be assessed in follow-up investigations. 
While previous studies have also suggested alterations in sodium 
channel subunits with an up-regulation of NaV1.3 in hippocampal in-
terneurons in a different Dravet mouse model (Yu et al., 2006), our data 
did not detect this protein in the Scn1a-A1783V mouse model. 
4.3. Astrogliosis, angiogenesis and NO signaling 
Reactive astrogliosis can promote hyperexcitability, affect inflam-
matory signaling, and disrupt integrity of the blood–brain barrier 
(Devinsky et al., 2013). Increased GFAP abundance provides evidence 
for astrogliosis in the Scn1a-A1783V mouse model. This finding is in line 
with previous reports describing astrogliosis in other mouse models of 
Dravet syndrome (Alonso Gómez et al., 2018; Hawkins et al., 2019). 
Alterations in the astrocytic functional state are further supported by 
evidence of a reduction of astroglial excitatory amino acid transporters 
(EAAT1 and EAAT2) and for an overexpression of the inward rectifying 
potassium channel Kir4.1 (KCNJ10). These findings may imply con-
trasting functional consequences; however, this requires confirmation 
by further investigations. 
Following seizure onset, we observed an additional regulation of 
ANXA2 and vimentin, which both act as modulators of VEGF signaling 
and angiogenesis (Dave and Bayless, 2014; Liu and Hajjar, 2016), pre-
viously discussed as a pro-epileptogenic factors and as a potential target 
for antiepileptogenesis (Morin-Brureau et al., 2012; Rigau et al., 2007). 
Proteomic profiling also revealed a dysregulation of nitric oxide 
Fig. 7. Immunohistochemical staining of representative proteins. A-B Representative immunohistochemical staining of PPP1R1B protein in the hippocampus (low 
magnification, A) and hippocampal CA1 region (high magnification, B). Pronounced protein immunostaining was particularly evident in the CA1 region of Dravet 
mice. C–D Immunohistochemical staining of HSD11B1 protein in the hippocampus (low magnification, C) and hippocampal hilar region (higher magnification, D). 
Protein immunoreactivity was reduced in Dravet mice, which was particularly evident in the hilus. Scale bars = 200 μm (A, C, D) and 50 μm (B). 
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(NO) signaling in Dravet mice with an increased expression of neuronal 
nitric oxide synthase (nNOS) following the onset of spontaneous recur-
rent seizures. Considering that NO can induce reactive glial proliferation 
and promote angiogenesis (Arhan et al., 2011; Morbidelli et al., 2004), 
dysregulated NO signaling might play a role in epileptogenesis and 
promoting hyperexcitability in the epileptic brain. 
4.4. Proteomic alterations before epilepsy manifestation 
While rather limited alterations were evident prior to epilepsy 
manifestation, they may be of interest as they might provide information 
about molecular mechanisms that occur as an early consequence of the 
SCN1A genetic deficiency thus potentially contributing to disease onset. 
In this context, the down-regulation of RASGRF1 might be of functional 
relevance as a contribution of RASGRF1 to epileptogenesis has been 
suggested based on a study with genetic and pharmacological targeting 
(Bao et al., 2018). Thus, it might be of interest to further explore a po-
tential contribution of early RASGRF1 down-regulation to disease 
manifestation and seizure onset in Dravet mice. 
4.5. Differentially expressed proteins across time points 
Proteome alterations in Dravet mice at the earlier time point were 
milder. Thereby the majority of dysregulated proteins were up- 
regulated. These molecular changes may represent a direct conse-
quence of the Scn1a deficiency. In contrast, proteomic data from Dravet 
mice following disease manifestation indicated more pronounced mo-
lecular alterations with the majority of dysregulated proteins showing a 
down-regulation. As discussed above, some of these alterations may not 
only be related to Scn1a genetic deficiency but may also represent a 
mechanism compensating for repetitive seizure activity or other path-
ophysiological mechanisms developing throughout the course of dis-
ease. Notwithstanding the observed differences in regulation, the 
molecular function of regulated proteins at both time points showed the 
same qualitative pattern with the majority of regulated proteins being 
classified as enzymes and binding molecules. Furthermore, the func-
tional annotation of differently expressed proteins revealed metabolite 
interconversion and protein modifying enzymes as the most common 
classification groups at both time points. These commonalities are 
Fig. 8. Glutamatergic synapse in Dravet mice (KEGG pathway). It is well known that Scn1a deficiency results in dysfunction of GABAergic interneurons (Catterall, 
2018), which causes hyperexcitability and lowered seizure thresholds. However, proteome analysis revealed that various proteins directly or indirectly associated 
with glutamatergic signaling are altered as a consequence of genetic Scn1a deficiency in the mouse model studied here. Significantly regulated proteins in two- and 
four-week-old Dravet mice are highlighted in blue and red, respectively. SHANK, PKA and PKC were the only proteins showing a dysregulation at the both time 
points, indicating that the dysregulation of glutamatergic synaptic transmission may being prior to disease manifestation. GLNS (GLUL) - glutamine synthetase; SN1 
(SLC38A3) - solute carrier family 38 member 3; EAAT (EAAT1_2_3) – excitatory amino acid transporters 1, 2 and 3; mGluR - metabotropic glutamate receptor; GLNT 
(SLC38A1) - solute carrier family 38 member 1; GLS – glutaminase; vGLUT (SLC17A6_7_8) - solute carrier family 17 member 6, 7 and 8; GRK - beta-adrenergic- 
receptor kinase; Gi/Go (GNAI) - guanine nucleotide-binding protein G(i) subunit alpha; AC (ADCY1) – adenylate cyclase 1; PKA – protein kinase A; GIRK 
(KCNJ3) - potassium inwardly-rectifying channel subfamily J member 3; VGCC (CACNA1A) - voltage-dependent calcium channel P/Q type alpha-1A; KA (GRIK1) - 
glutamate ionotropic kainate receptor 1; AMPA (GRIA1) – glutamate receptor 1; NMDAR (GRIN1) - glutamate ionotropic receptor; TRPC1 - transient receptor 
potential cation channel subfamily C member 1; PSD95 – postsynaptic density protein 95; SHANK - SH3 and multiple ankyrin repeat domains protein; GKAP 
(DLGAP1) – discs large-associated protein 1; PP2B (PPP3C)- serine/threonine-protein phosphatase 2B catalytic subunit; Gq (GNAQ) - guanine nucleotide-binding 
protein G(q) subunit alpha; PLC (PLCB) - phosphatidylinositol phospholipase C beta; PKC (PRKCA) - classical protein kinase C alpha type; PLA2 (PLA2G4) - cyto-
solic phospholipase A2; IP3R (ITPR1) - inositol 1,4,5-triphosphate receptor type 1; PLD (PLD1_2) - phospholipase D1 and 2; ERK1/2 (MAPK1_3) - mitogen-activated 
protein kinase 1 and 3. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
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particularly apparent with glutamatergic signaling, as one of the dys-
regulated cellular processes following disease manifestation (Fig. 8). 
Changes in the expression of proteins with binding and catalytic activity, 
SHANK3 and subunits of protein kinases A and C (PRKAR1A, PRKCA), 
also suggest a possible dysregulation of glutamatergic synaptic trans-
mission prior to spontaneous seizure onset. In this context, it is 
emphasized that it is well accepted that the dysfunction of GABAergic 
interneurons is the main mechanism of hyperexcitability in SCN1A- 
related Dravet syndrome (Catterall, 2018). However, data from the 
mouse model studied here indicates that the expression pattern of pro-
teins directly or indirectly linked with glutamatergic signaling can be 
affected in a complex manner as a consequence of Scn1a genetic 
deficiency. 
5. Study limitations 
Considering the whole proteome approach applied to hippocampal 
samples and the characteristics of the mouse model, respective limita-
tions need to be considered. 
Firstly, disease manifestation occurs early on in Dravet mice result-
ing in delayed postnatal bodyweight development. This in itself may 
impact molecular alterations in the brain. 
Moreover, considering that untargeted proteomic studies are limited 
to screening proteins in the entire sample, further studies investigating 
the expression patterns in different hippocampal sub-regions and cell 
types along with studies addressing the functional consequences are 
needed to elucidate the functional relevance of these findings. The 
present findings provide a basis to design respective studies applying 
targeted proteomic approaches. 
However, in this context the limitations of bulk approaches should be 
taken into account. In particular, bulk approaches can imply the risk to 
miss alterations, which only occur in a cellular subpopulation, but may 
nevertheless be biologically or pathologically relevant. 
Moreover, it needs to be considered that seizure activity per se can 
trigger molecular changes, which are not necessarily associated with 
functional implications. Thus, it remains impossible to conclude about a 
cause and effect relationship and a potential functional relevance of the 
molecular changes observed in this proteome analysis. Thus, as 
repeatedly emphasized, it is of utmost relevance to assess the functional 
implications of these findings in future studies. 
6. Conclusions 
In conclusion, the whole proteome analysis in a mouse model of 
Dravet syndrome demonstrated complex molecular alterations in the 
hippocampus as a consequence of the genetic deficiency. Some of these 
alterations may have an impact on excitability or may serve compen-
satory functions, which should be further investigated. 
Moreover, the proteomic data indicate that, due to the molecular 
consequences of the genetic deficiency, the pathophysiological mecha-
nisms become more complex over the course of the disease. Resultantly, 
the management of Dravet syndrome may need to consider further 
molecular and cellular alterations. Functional follow-up studies are 
therefore required to confirm our findings and may provide valuable 
guidance for the development of novel therapeutic approaches. 
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